OSR Holdings Secures Complete VXM01 IP Portfolio in $30 Million Deal with Vaximm AG

OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare holding company specializing in innovative therapeutics and healthcare technologies, announced on May 27, 2026, that it has entered into a definitive Asset Purchase Agreement (APA) with Vaximm AG to acquire the full global intellectual property portfolio and related assets for the VXM01 program. The aggregate purchase price for the transaction is $30 million.

This acquisition follows OSR Holdings' previously disclosed definitive global exclusive license agreement with BCM Europe AG (BCME), executed on April 29, 2026, which grants BCME rights to develop, commercialize, and potentially sublicense VXM01. That license agreement includes milestone payments of up to $815 million tied to development and commercialization benchmarks.

Under the terms of the APA, OSR Holdings will obtain the complete VXM01 intellectual property portfolio, which encompasses issued and pending patents across major jurisdictions including the United States, Canada, Europe, Japan, China, Korea, and other territories. The patent protection extends through 2038, securing long-term exclusivity for the technology.

Peter Hwang, CEO of OSR Holdings, emphasized the strategic importance of the acquisition, stating, "This acquisition advances our strategy of centralizing high-value intellectual property assets at the OSRH parent level. Under our hub-and-spoke operating model, OSRH acts as the central IP owner, while development and commercialization are executed through affiliated entities and partners. This enhances licensing flexibility and long-term royalty economics, with value accruing to OSRH shareholders."

The existing global exclusive license agreement with BCME provides OSR Holdings with eligibility for up to $815 million in development and commercial milestone payments. BCME has pledged its entire unencumbered OSRH equity stake as collateral for these milestone obligations. Additionally, OSR retains rights to 100% of downstream royalty economics after BCME recovers costs and preferred returns.

OSR Holdings also holds a $15 million put option exercisable at $10.00 per share, which becomes available six months after the effective date of the licensing agreement.

According to the APA, the $30 million purchase price is payable upon the occurrence of the first milestone event under the BCME License Agreement. This milestone is defined as the completion of a Phase 2 clinical study (Phase 2b or equivalent) of VXM01 in either glioblastoma (GBM) or pancreatic ductal adenocarcinoma (PDAC). The agreement also allows OSR Holdings to make voluntary partial payments before this milestone event.

The centralized ownership of the VXM01 intellectual property portfolio is expected to facilitate future evaluations of innovative financing and royalty participation structures related to the VXM01 platform. OSR Holdings has indicated that it will provide additional updates as appropriate.

VXM01 is a clinical-stage oral immunotherapy designed to target vascular endothelial growth factor receptor 2 (VEGFR-2). It aims to induce a targeted immune response against tumor vasculature and modulate the tumor microenvironment. The program has demonstrated encouraging clinical activity and immune activation in studies involving glioblastoma and pancreatic cancer, two of the most challenging solid tumors to treat.

VXM01 is currently being developed by Vaximm AG, a wholly owned subsidiary of OSR Holdings, underscoring OSR’s integrated approach to advancing this innovative therapeutic candidate.